Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Newcorn, J. H. Search for Related Content PubMed Citation Articles by Newcorn, J. H. Attention Deficit Hyperactivity Disorder Other Somatic Therapy Related Articles

Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response

Atomoxetine/Methylphenidate Comparative Study Group

OBJECTIVE: Response to atomoxetine, a nonstimulant norepinephrine-specific reuptake inhibitor, was compared with the effect of osmotic-release oral methylphenidate, a long-acting methylphenidate preparation, in patients with attention deficit hyperactivity disorder (ADHD). METHOD: In a large placebo-controlled, double-blind study, patients ages 6–16 with ADHD, any subtype, were randomly assigned to receive 0.8–1.8 mg/kg per day of atomoxetine (N=222), 18–54 mg/day of osmotically released methylphenidate (N=220), or placebo (N=74) for 6 weeks. The a priori specified primary analysis compared response (at least 40% decrease in ADHD Rating Scale total score) to osmotically released methylphenidate with response to atomoxetine and placebo. After 6 weeks, patients treated with methylphenidate were switched to atomoxetine under double-blind conditions. RESULTS: The response rates for both atomoxetine (45%) and methylphenidate (56%) were markedly superior to that for placebo (24%), but the response to osmotically released methylphenidate was superior to that for atomoxetine. Each medication was well tolerated, with completion rates and discontinuations for adverse events not significantly different from those for placebo. Of the 70 subjects who did not respond to methylphenidate, 30 (43%) subsequently responded to atomoxetine. Likewise, 29 (42%) of the 69 patients who did not respond to atomoxetine had previously responded to osmotically released methylphenidate. CONCLUSION: Response was significantly greater with osmotically released methylphenidate than with atomoxetine. One-third of patients who received methylphenidate followed by atomoxetine responded better to one or the other, suggesting that there may be preferential responders.

Related Articles:

Improving Decision Making in the Treatment of ADHD

Benedetto Vitiello
Am J Psychiatry 2008 165: 666-667. [Full Text] [PDF]

This article has been cited by other articles:

				M. McLeod, T. Laubscher, L. Regier, and B. Jensen Taking the stress out of individualizing ADHD drug therapy Can Fam Physician, September 1, 2009; 55(9): 895 - 898. [Full Text] [PDF]

				G. Bates Drug treatments for attention-deficit hyperactivity disorder in young people Adv. Psychiatr. Treat., May 1, 2009; 15(3): 162 - 171. [Abstract] [Full Text] [PDF]

				B. Vitiello Improving Decision Making in the Treatment of ADHD Am J Psychiatry, June 1, 2008; 165(6): 666 - 667. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us